

intravascularly, or subcutaneously, intraperitoneally, by topical drops or ointment, periocular injection, systemically by intravenous injection or orally, intracamerally into the anterior chamber or vitreous, via a depot attached to the intraocular lens implant inserted during surgery, or via a depot placed in the eye sutured in the anterior chamber or vitreous.

REMARKS

Claims 1-17 are pending in the subject Application. Applicant has amended Claim 1 to delete the word "antagonizes" which appeared twice and Claims 16 and 17 to correct the dependency and a typographical error.

Attached hereto is a marked-up version of the changes made to the subject. The attached page is captioned "Version With Markings To Show Changes Made".

In the Office Action, the Examiner asserted that restriction of the claimed invention to one of the 24 suggested groups is required under 35 U.S.C. §121.


In response, Applicant elect with traverse Group V, which is directed to anti-TNF α antibody. The following claims are readable on the elected group: 1, 2, 5, 6, 9, 11, 12, 13, 14, 16 and 17. Claim 1 being general method for treating a subject with glaucoma comprising administration of an agent which antagonizes, inhibits, reduces, suppresses, and/or limits the release, synthesis or production of TNF α .

Traversal is made for the following reasons: The subject matter of the other groups may be searched together with the subject matter of anti-TNF α antibody group and hence would not be a burdensome search for the Examiner.

Lastly, in accordance with this restriction with traverse, Applicants reserve all rights in the claims that include all the groups to file divisional and/or continuation patent applications.

Applicants: Martin B. Wax
File No.: P-3023-US1
Serial No.: 09/591,561
Page 3 of 2

No fee is deemed necessary for filing this Communication. However, if any fee is required, the undersigned Attorney hereby authorizes the United States Patent and Trademark Office to charge Deposit Account 05-0649.


Respectfully Submitted,

Mark S. Cohen
Registration No. 42,425
Attorney for Applicants

Date: September 30, 2001

Eitan. Pearl, Latzer & Cohen-Zedek
Crystal Park, Suite 210
2011 Crystal Drive
Arlington, VA 22202
Tel: (703) 486-1177
Fax: (703) 486-0800

Applicants: Martin B. Wax
File No.: P-3023-US1
Serial No.: 09/591,561
Page 4 of 2



TECH CENTER 1600 2900

OCT 05 2001

RECEIVED

VERSION WITH MARKINGS TO SHOW CHANGES MADE

1. A method for treating a subject with glaucoma comprising the steps of administering a compound or composition containing an agent or molecule, which antagonizes, inhibits, inactivates, reduces, suppresses, [antagonizes], and/or limits the release, synthesis, or production from cells of TNF- α thereby treating the subject with glaucoma.
16. The method of claim 1, wherein said [A pharmaceutical composition comprising the] compound or composition [of Claim 1 and] further comprises a diluent and suitable carrier.
17. The method of claim 1, wherein the compound or composition is administered ocularly, parenterally, transmucosally, transdermally, intramuscularly, intravenously, intradermally, intravascularly, or subcutaneously, [intraperitoneally] intraperitoneally, by topical drops or ointment, periocular injection, systemically by intravenous injection or orally, intracamerally into the anterior chamber or vitreous, via a depot attached to the intraocular lens implant inserted during surgery, or via a depot placed in the eye sutured in the anterior chamber or vitreous.